Vitamin K supplementation for the primary prevention of osteoporotic fractures: Is it cost-effective and is future research warranted?

Osteoporosis International

Volumn 23, Issue 11, 2012, Pages 2681-2692

  Gajic Veljanoski, O ^a,b   Bayoumi, A M ^a,c,d   Tomlinson, G ^a,c   Khan, K ^a,c,d   Cheung, A M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Expected value of perfect information (EVPI); Fracture prevention; Postmenopausal; Vitamin K

Indexed keywords

CALCIUM; COLECALCIFEROL; FARNOQUINONE; VITAMIN K GROUP;

ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAGILITY FRACTURE; HUMAN; MORTALITY; OVERALL SURVIVAL; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; THERAPY EFFECT; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; CALCIUM; CANADA; CHOLECALCIFEROL; COST-BENEFIT ANALYSIS; DIETARY SUPPLEMENTS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; VITAMIN K 1; VITAMIN K 2;

EID: 84868199240     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1939-4     Document Type: Article

References (70)

1. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256-1261
2. Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R (2008) Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Medicine 5: e196
3. Volpe SL, Leung MM, Giordano H (2008) Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women. Nutr Res 28:577-582
4. Emaus N, Gjesdal CG, Almas B, Christensen M, Grimsgaard AS, Berntsen GKR, Salomonsen L, Fonnebo V (2010) Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporos Int 21:1731-1740
5. Booth SL, Dallal G, Shea MK, Gundberg C, Peterson JW, Dawson-Hughes B (2008) Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 93:1217-1223
6. Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, Prynne CJ, Mishra GD, Shearer MJ (2007) Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 22:509-519
7. Binkley N, Harke J, Krueger D, Engelke J, Vallarta-Ast N, Gemar D, Checovich M, Chappell R, Suttie J (2009) Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res 24:983-991
8. Fang Y, Hu C, Tao X, Wan Y, Tao F (2012) Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J Bone Miner Metab 30(1):60-68. doi:10.1007/s00774-011-0287-3
9. Eckermann S, Willan AR (2007) Expected value of information and decision making in HTA. Health Econ 16:195-209
10. Claxton K (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18:341-364
11. Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253-1258
13. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417-427
14. Melton LJ III, Thamer M, Ray NF, Chan JK, Chesnut CH III, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16-23
15. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26
16. National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
17. The Medical Letter (2008) Drugs for postmenopausal osteoporosis. The Medical Letter 6:67-74
18. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis: the European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390-406
19. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995
20. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
21. Hodsman AB, Leslie WD, Tsang JF, Gamble GD (2008) 10-Year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med 168:2261-2267
22. Statistics Canada (2007) Canada national statistics life tables (2000-2002). Statistics Canada. http://www.statcan.gc.ca/pub/84-537-x/t/ txttables/caf.txt. Accessed 27 Jun 2011
23. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468-473
24. Melton LJ III (2000) Excess mortality following vertebral fracture. J Am Geriatr Soc 48:338-339
25. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670-676
26. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebocontrolled trial. Lancet 365:1621-1628
27. Jackson RD, LaCroix AZ, Gass M, Women's Health Initiative Investigators et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669-683
28. Shiraki M, Shiraki Y, Aoki C, Miura M (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521
29. Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, Asano Y (2005) Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 23:41-47
30. Iwamoto J, Takeda T, Ichimura S (2001) Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci 6:487-492
31. Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 117:549-555
32. Sato Y, Honda Y, Kuno H, Oizumi K (1998) Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D-and K-deficient stroke patients. Bone 23:291-296
33. Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K (2002) Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 31:114-118
34. Sato Y, Kanoko T, Satoh K, Iwamoto J (2005) Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone 36:61-68
35. Stevenson M, Jones ML, De NE, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1-160
36. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
37. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875-883
38. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ III (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042-1049
39. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384-1392
40. Dolan P, Torgerson D, Kakarlapudi TK (1999) Health-related quality of life of Colles' fracture patients. Osteoporos Int 9:196-199
41. Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621-635
42. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475
43. Mansley EC, Carroll NV, Chen KS, Shah ND, Piech CT, Hay JW, Smeeding J (2009) Good Research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force Report - part III. Value Health 13:14-17
44. NSI Vitamin K-1. http://wwwvitacost.com/NSI-Vitamin-K-1?csrc0NTDC- 835003001361#IngredientFacts. Accessed 27 Jun 2011
45. Glakay. http://wwwpharmaoffshorecom/indexphp?cPath0426. Accessed 27 Jun 2011
46. Glakay (brand). http://buyaldaracream.com/pharma/product-info.php? manufacturers-id06&products-id0602& osCsid0fd41e6b123f51563354559dd25c5dc18. Accessed 27 Jun 2011
47. Consumer Price Index - December 2009. http://www.bls.gov/cpi/. Accessed 27 Jun 2011
48. Briggs A, Fenn P (1998) Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 7:723-740
49. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS (2002) Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22:417-430
50. Cantor SB (1994) Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 14:259-265
51. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521
52. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-112
53. US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. US Department of Health and Human Services, Office of the Surgeon General, Rockville
54. Stevenson M, Lloyd-Jones M, Papaioannou D (2009) Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess 13:iii-ix, 1-134
55. Stevenson MD, Jones ML (2011) The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate. Med Decis Making 31:43-52
56. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD (2010) 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864-1873
57. Leslie WD, Morin S, Lix LM (2010) A before-and-after study of fracture risk reporting and osteoporosis treatment initiation. Ann Intern Med 153:580-586
58. Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA, Ioannidis G, Josse RG, Kovacs CS, Towheed T, Kaiser S, Olszynski WP, Prior JC, Jamal S, Kreiger N, Goltzman D (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22:1873-1883
59. Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Construction of a FRAX(R) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 22:817-827
60. Booth SL (2009) Roles for vitamin K beyond coagulation. Annu Rev Nutr 29:89-110
61. Knapen MH, Hamulyak K, Vermeer C (1989) The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 111:1001-1005
62. Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047
63. Vermeer C, Jie KS, Knapen MH (1995) Role of vitamin K in bone metabolism. Annu Rev Nutr 15:1-22
64. Iwamoto J, Matsumoto H, Takeda T (2009) Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Clin Drug Investig 29:471-479
65. Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B (2003) Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919-43927
66. Reddi K, Henderson B, Meghji S, Wilson M, Poole S, Hopper C, Harris M, Hodges SJ (1995) Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine 7:287-290
67. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071
68. Hara K, Akiyama Y, Tajima T, Shiraki M (1993) Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J Bone Miner Res 8:535-542
69. Hara K, Akiyama Y, Nakamura T, Murota S, Morita I (1995) The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 16:179-184
70. Iwamoto J, Takeda T, Sato Y (2006) Menatetrenone (vitamin K2) and bone quality in the treatment of postmenopausal osteoporosis. Nutr Rev 64:509-517